

# LIVER CANCER

Liver Cancer, or Hepatocellular carcinoma, is the third most common cause of cancer death, yet there is only one approved systemic therapy available. High unmet need has created a demand in the development pipeline.

## A Deadly Disease



Liver Cancer accounts for

# 700,000

deaths annually. That's the population of a city the size of Charlotte, NC.

**5<sup>th</sup>**  
**most common cancer among men**

1. Lung
2. Prostate
3. Colon
4. Stomach
5. Liver
6. Oesophagus
7. Bladder
8. Non-Hodgkin lymphoma


**8<sup>th</sup>**  
**most common cancer among women**

3. Cervix uteri
4. Lung
5. Stomach
6. Corpus Uteri
7. Ovary
8. Liver

**3RD MOST COMMON CAUSE OF CANCER DEATH.**

## Nexavar

(sorafenib)



Sorafenib is the only drug available for liver cancer, but it has a few drawbacks:

- Only approved for patients with well-preserved liver function and advanced, unresectable tumors
- Reduces in effectiveness over time as patients develop resistance to the treatment
- Increases median survival rate from 6 months to 11 months

## High Unmet Need

Poor survival rates

Presence of significant comorbidities

Lack of effective treatment options.

Late diagnosis

## Orphan Disease


Orphan Diseases, like Liver Cancer, either affect fewer than

# 200,000 people

people in the U.S. each year, or are not expected to recover the costs of developing and marketing a treatment drug. The FDA provides grants to fund clinical research for these rare diseases.

## Development Pipeline

There are 10 drugs in the later stages of the development pipeline, all of which are somewhere within Phase III.



### Sources

- [1] EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology 2012 vol. 56 j 908-943
- [2] Centers for Disease Control and Prevention. Yellow Book 2012 (CDC Health Information for International Travel). Accessed through website: Eyasu H. Teshale <http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/hepatitis-b.htm#2403>
- [3] Centers for Disease Control and Prevention. Yellow Book 2012 (CDC Health Information for International Travel). Accessed through website: Scott Holmberg <http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/hepatitis-c.htm>
- [4] Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Am J Gastroenterol. 2013 Feb 5. Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis.
- [5] Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: <http://globocan.iarc.fr>.
- [6] American Cancer Society. Cancer Facts and Figures 2013. Accessed through website: <http://www.cancer.org/acs/groups/content/@epidemiologysurveillance/documents/document/acspc-036845.pdf>

Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise. For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at [www.ISRreports.com](http://www.ISRreports.com), email [info@ISRreports.com](mailto:info@ISRreports.com), or follow us on twitter @ISRreports.



[www.ISRreports.com](http://www.ISRreports.com)